EB Research Project Grants
Supports Venture philanthropy grants for commercially viable EB therapy research, with royalty bearing terms and renewable funding years.
EB Research Project Grants sit under EB Research Partnership and DEBRA of America, a New York 501(c)(3) nonprofit founded in 2010 to accelerate research toward treating and curing epidermolysis bullosa. The program is the partnership's main translational route for projects that can reach a commercial or clinical result within one to four years. Awards are structured as one-year grants that can be renewed annually for up to five years, and the model is explicitly venture philanthropy: EBRP retains a royalty or financial interest in successful projects and reinvests the return in additional EB research. Eligible work can include drug repurposing, pre-clinical or clinical studies, and research tools such as data platforms, while basic research without a clear commercial path is not a fit. The public page also calls for Humane Care documentation, Human Subjects approvals, and a 5% cap on indirect costs, but it does not publish award sizes. The strongest proposals are the ones that can show near-term therapeutic relevance and a credible route to development, not just scientific novelty. EBRP's own mission language emphasizes business discipline alongside scientific rigor, so applicants need milestones, translational logic, and a plan for how the work could become a therapy or product if it succeeds. The second 2026 cycle opens in August and closes in September, which leaves a narrow submission window for teams that are already organized.
Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.